ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer.

ABSTRACT: Because traditional treatment strategies for advanced gastrointestinal (GI) cancers often have a limited therapeutic effect, immunotherapy could be a viable approach for the therapy of advanced GI cancers, considering the recent success of immunotherapy in treating various refractory malignancies, including the DNA mismatch repair-deficient GI cancers. However, only a subset of cancer patients currently respond to immunotherapy. Thus, it is important to identify useful biomarkers for predicting cancer immunotherapy response. The tumor suppressor gene ARID1A has a high mutation rate in GI cancers and its deficiency is correlated with the microsatellite instability (MSI) genomic feature of cancer. We investigated the correlation between ARID1A mutations and tumor immunity using

SUBMITTER: Li L 

PROVIDER: S-EPMC6678467 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature